P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours.

Baltaci, S; Orhan, D; Turkolmez, KADİR; Yesilli, C; Beduk, Y; Tulunay, O

doi:10.1046/j.1464-410x.2001.02151.x

P53, bcl-2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours.

Copy For Citation

Baltaci S., Orhan D., Turkolmez K., Yesilli C., Beduk Y., Tulunay O.

BJU international, vol.87, no.7, pp.661-6, 2001 (SCI-Expanded)

Publication Type: Article / Article
Volume: 87 Issue: 7
Publication Date: 2001
Doi Number: 10.1046/j.1464-410x.2001.02151.x
Journal Name: BJU international
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.661-6
Keywords: p53, bcl-2, bax, testis cancer, chemoresistance, TESTIS CANCER, TUMORS, GENE, APOPTOSIS, MUTATIONS, DEATH, RISK, EXPRESSION, ETOPOSIDE, CLONING
Ankara University Affiliated: Yes

Abstract

Objective To evaluate the roles of p53, bcl-2 and bax as determinants of chemosensitivity in testicular cancers and to assess whether immunohistochemical expression of these proteins in testicular germ cell tumours (GCTs) could be used to predict the outcome in patients with metastatic testicular GCTs.